Cargando…

Cortical metabolic and structural differences in patients with chronic migraine. An exploratory (18)FDG-PET and MRI study

BACKGROUND: To describe interictal brain structural and metabolic differences between patients with episodic migraine (EM), chronic migraine (CM) and healthy controls (HC). METHODS: This is an exploratory study including right-handed age-matched women with EM, CM and HC. On the same day, a sequentia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres-Ferrus, Marta, Pareto, Deborah, Gallardo, Victor J, Cuberas-Borrós, Gemma, Alpuente, Alicia, Caronna, Edoardo, Vila-Balló, Adrià, Lorenzo-Bosquet, Carles, Castell-Conesa, Joan, Rovira, Alex, Pozo-Rosich, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285838/ https://www.ncbi.nlm.nih.gov/pubmed/34273945 http://dx.doi.org/10.1186/s10194-021-01289-5

Ejemplares similares

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
por: Alpuente, Alicia, et al.
Publicado: (2021)

A study of differential microRNA expression profile in migraine: the microMIG exploratory study
por: Gallardo, V. J., et al.
Publicado: (2023)

Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task
por: Marti-Marca, Angela, et al.
Publicado: (2023)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
por: Caronna, Edoardo, et al.
Publicado: (2018)

Neuroimaging, neuropsychological and psychopathological findings in Medication Overuse Headache (MOH) before and after detoxification
por: Pozo-Rosich, P, et al.
Publicado: (2013)

Estimation of the density of veins from susceptibility-weighted imaging by using Mamdani fuzzy-type rule-based system. Investigating the neurovascular coupling in migraine
por: González, R., et al.
Publicado: (2023)

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study
por: Cuberas-Borrós, Gemma, et al.
Publicado: (2022)

Impact of Puberty in Pediatric Migraine: A Pilot Prospective Study
por: Fonseca, Elena, et al.
Publicado: (2020)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

EHMTI-0361. Lack of differences in microrna expression profiles of blood cells in migraine
por: Vila-Pueyo, M, et al.
Publicado: (2014)

Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
por: Caronna, Edoardo, et al.
Publicado: (2021)

InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers
por: Gago-Veiga, AB, et al.
Publicado: (2021)

The Role of Glial Cells in Different Phases of Migraine: Lessons from Preclinical Studies
por: Vila-Pueyo, Marta, et al.
Publicado: (2023)

The influence of temporal unpredictability on the electrophysiological mechanisms of neural entrainment
por: Vilà‐Balló, Adrià, et al.
Publicado: (2022)

Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution
por: Caronna, Edoardo, et al.
Publicado: (2020)

EHMTI-0048. Epigenetic changes in a rat model of migraine with aura
por: Vila-Pueyo, M, et al.
Publicado: (2014)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials
por: Reuter, Uwe, et al.
Publicado: (2019)

EHMTI-0270. Experience with onabotulinumtoxin type a in high-frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

EHMTI-0283. Predictors of early response to onabotulinumtoxin type a in chronic migraine
por: Mas-Sala, N, et al.
Publicado: (2014)

Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer’s Disease Patients Treated with Plasma Exchange with 5% Human Albumin
por: Cuberas-Borrós, Gemma, et al.
Publicado: (2017)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

EHMTI-0288. A clinical comparison demonstrates similarities between chronic and high frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
por: Steiner, Timothy J, et al.
Publicado: (2022)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Usefulness of FDG PET/CT in the management of tuberculosis
por: Sánchez-Montalvá, Adrián, et al.
Publicado: (2019)

From transformation to chronification of migraine: pathophysiological and clinical aspects
por: Torres-Ferrús, M., et al.
Publicado: (2020)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas
por: Irimia, P., et al.
Publicado: (2021)

Cerebrovascular Function in Hormonal Migraine: An Exploratory Study
por: Dzator, Jemima S. A., et al.
Publicado: (2021)

Mode and site of action of therapies targeting CGRP signaling
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2023)

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
por: Sacco, Simona, et al.
Publicado: (2020)

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
por: Sacco, Simona, et al.
Publicado: (2021)

Quantitative techniques in (18)FDG PET scanning in oncology
por: Castell, F, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_k5v6psloh969k4r9osknbdp1ev